Drug Trial Radar · NCT05268666
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
126
Planned (sponsor's estimate)
Start
Apr 8, 2022
Primary completion
Dec 2024
Study completion Aug 2025
Sponsor
- Lead sponsor
- Jubilant Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine differentiation.
Conditions
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
JBI-802Drug
LSD1/HDAC6 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum-Tolerated Dose (MTD)Time frame: 28-day cycle
- Investigator-Assessed ORR (Part 2)Time frame: Up to 30 days from the last dose of study drug
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Sarah Cannon Research Institute at HealthOne
Denver, Colorado · Completed
The Christ Hospital
Cincinnati, Ohio · Recruiting
Tennessee Oncology, PLLC
Nashville, Tennessee · Completed
NEXT Virginia, LLC
Fairfax, Virginia · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.